Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia.


Journal

Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895

Informations de publication

Date de publication:
05 2021
Historique:
received: 04 09 2020
accepted: 12 03 2021
revised: 04 02 2021
pubmed: 1 4 2021
medline: 16 6 2021
entrez: 31 3 2021
Statut: ppublish

Résumé

The prevalence and functional impact of somatic mutations in nonleukemic T cells is not well characterized, although clonal T-cell expansions are common. In immune-mediated aplastic anemia (AA), cytotoxic T-cell expansions are shown to participate in disease pathogenesis. We investigated the mutation profiles of T cells in AA by a custom panel of 2533 genes. We sequenced CD4+ and CD8+ T cells of 24 AA patients and compared the results to 20 healthy controls and whole-exome sequencing of 37 patients with AA. Somatic variants were common both in patients and healthy controls but enriched to AA patients' CD8+ T cells, which accumulated most mutations on JAK-STAT and MAPK pathways. Mutation burden was associated with CD8+ T-cell clonality, assessed by T-cell receptor beta sequencing. To understand the effect of mutations, we performed single-cell sequencing of AA patients carrying STAT3 or other mutations in CD8+ T cells. STAT3 mutated clone was cytotoxic, clearly distinguishable from other CD8+ T cells, and attenuated by successful immunosuppressive treatment. Our results suggest that somatic mutations in T cells are common, associate with clonality, and can alter T-cell phenotype, warranting further investigation of their role in the pathogenesis of AA.

Identifiants

pubmed: 33785863
doi: 10.1038/s41375-021-01231-3
pii: 10.1038/s41375-021-01231-3
pmc: PMC8102188
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1365-1379

Références

Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2509–19.
pubmed: 16778145 pmcid: 1895575 doi: 10.1182/blood-2006-03-010777
Luzzatto L, Risitano AM. Advances in understanding the pathogenesis of acquired aplastic anaemia. Br J Haematol. 2018;182:758–76.
Young NS. Aplastic anemia. N Engl J Med. 2018;379:1643–56.
pubmed: 30354958 pmcid: 6467577 doi: 10.1056/NEJMra1413485
Mortazavi Y, Chopra R, Gordon-Smith EC, Rutherford TR. Clonal patterns of X-chromosome inactivation in female patients with aplastic anaemia studies using a novel reverse transcription polymerase chain reaction method. Eur J Haematol. 2000;64:385–95.
Afable MG, Wlodarski M, Makishima H, Shaik M, Sekeres MA, Tiu RV, et al. SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood. 2011;117:6876–84.
pubmed: 21527527 pmcid: 3128479 doi: 10.1182/blood-2010-11-314393
Mikhailova N, Sessarego M, Fugazza G, Caimo A, De Filippi S, van Lint MT, et al. Cytogenetic abnormalities in patients with severe aplastic anemia. Haematologica. 1996;81:418–22.
pubmed: 8952154
Katagiri T, Sato-Otsubo A, Kashiwase K, Morishima S, Sato Y, Mori Y, et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood. 2011;118:6601–9.
pubmed: 21963603 doi: 10.1182/blood-2011-07-365189
Tichelli A, Gratwohl A, Würsch A, Nissen C, Speck B. Late haematological complications in severe aplastic anaemia. Br J Haematol. 1988;69:413–8.
Lane AA, Odejide O, Kopp N, Kim S, Yoda A, Erlich R, et al. Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia. 2013;27:968–71.
Kulasekararaj AG, Jiang J, Smith AE, Mohamedali AM, Mian S, Gandhi S, et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood. 2014;124:2698–704.
pubmed: 25139356 pmcid: 4383793 doi: 10.1182/blood-2014-05-574889
Heuser M, Schlarmann C, Dobbernack V, Panagiota V, Wiehlmann L, Walter C, et al. Genetic characterization of acquired aplastic anemia by targeted sequencing. Haematologica. 2014;99:e165–7.
pubmed: 24907358 pmcid: 4562551 doi: 10.3324/haematol.2013.101642
Babushok DV, Perdigones N, Perin JC, Olson TS, Ye W, Roth JJ, et al. Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia. Cancer Genet. 2015;208:115–28.
pubmed: 25800665 pmcid: 4433860 doi: 10.1016/j.cancergen.2015.01.007
Yoshizato T, Dumitriu B, Hosokawa K, Makishima H, Yoshida K, Townsley D, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015;373:35–47.
pubmed: 26132940 pmcid: 7478337 doi: 10.1056/NEJMoa1414799
Albitar A, Townsley D, Ma W, De Dios I, Funari V, Young NS, et al. Prevalence of somatic mutations in patients with aplastic anemia using peripheral blood cfDNA as compared with BM. Leukemia. 2018;32:227–9.
pubmed: 28832022 doi: 10.1038/leu.2017.271
Ogawa S. Clonal hematopoiesis in acquired aplastic anemia. Blood. 2016;128:337–47.
pubmed: 27121470 pmcid: 5054460 doi: 10.1182/blood-2016-01-636381
Risitano AM, Maciejewski JP, Green S, Plasilova M, Zeng W, Young NS. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet. 2004;364:355–64.
pubmed: 15276395 doi: 10.1016/S0140-6736(04)16724-X
Giudice V, Feng X, Lin Z, Hu W, Zhang F, Qiao W, et al. Deep sequencing and flow cytometric characterization of expanded effector memory CD8+CD57+ T cells frequently reveals T-cell receptor Vβ oligoclonality and CDR3 homology in acquired aplastic anemia. Haematologica. 2018;103:759–69.
pubmed: 29419434 pmcid: 5927970 doi: 10.3324/haematol.2017.176701
Li B, Guo L, Zhang Y, Xiao Y, Wu M, Zhou L, et al. Molecular alterations in the TCR signaling pathway in patients with aplastic anemia. J Hematol Oncol. 2016;9:32–9.
pubmed: 27036622 pmcid: 4818392 doi: 10.1186/s13045-016-0261-6
Li B, Liu S, Niu Y, Fang S, Wu X, Yu Z, et al. Altered expression of the TCR signaling related genes CD3 and FcεRIγ in patients with aplastic anemia. J Hematol Oncol. 2012;5:6–7.
pubmed: 22401598 pmcid: 3359239 doi: 10.1186/1756-8722-5-6
Sheng W, Liu C, Fu R, Wang H, Qu W, Ruan E, et al. Abnormalities of quantities and functions of linker for activations of T cells in severe aplastic anemia. Eur J Haematol. 2014;93:214–23.
Savola P, Kelkka T, Rajala HL, Kuuliala A, Kuuliala K, Eldfors S, et al. Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis. Nat Commun. 2017;8:15869.
Savola P, Brück O, Olson T, Kelkka T, Kauppi MJ, Kovanen PE, et al. Somatic STAT3 mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia. Haematologica. 2018;103:304–12.
pubmed: 29217783 pmcid: 5792275 doi: 10.3324/haematol.2017.175729
Kawakami T, Sekiguchi N, Kobayashi J, Imi T, Matsuda K, Yamane T, et al. Frequent STAT3 mutations in CD8+ T cells from patients with pure red cell aplasia. Blood Adv. 2018;2:2704–12.
pubmed: 30337298 pmcid: 6199660 doi: 10.1182/bloodadvances.2018022723
Valori M, Jansson L, Kiviharju A, Ellonen P, Rajala H, Awad SA, et al. A novel class of somatic mutations in blood detected preferentially in CD8+ cells. Clin Immunol. 2017;175:75–81.
pubmed: 27932211 pmcid: 5341785 doi: 10.1016/j.clim.2016.11.018
Van Horebeek L, Hilven K, Mallants K, Van Nieuwenhuijze A, Kelkka T, Savola P, et al. A robust pipeline with high replication rate for detection of somatic variants in the adaptive immune system as a source of common genetic variation in autoimmune disease. Hum Mol Genet. 2019;28:1369–80.
pubmed: 30541027 doi: 10.1093/hmg/ddy425
Kim D, Park G, Huuhtanen J, Lundgren S, Khajuria RK, Hurtado AM, et al. Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease. Nat Commun. 2020;11:2246–17.
Koskela HLM, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366:1905–13.
pubmed: 22591296 pmcid: 3693860 doi: 10.1056/NEJMoa1114885
Jerez A, Clemente MJ, Makishima H, Koskela H, LeBlanc F, Peng Ng K, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012;120:3048–57.
pubmed: 22859607 pmcid: 3471515 doi: 10.1182/blood-2012-06-435297
Andersson EI, Tanahashi T, Sekiguchi N, Gasparini VR, Bortoluzzi S, Kawakami T, et al. High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. Blood. 2016;128:2465–8.
pubmed: 27697773 pmcid: 5114490 doi: 10.1182/blood-2016-06-724856
Jerez A, Clemente MJ, Makishima H, Rajala H, Gómez-Seguí I, Olson T, et al. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 2013;122:2453–9.
pubmed: 23926297 pmcid: 3790512 doi: 10.1182/blood-2013-04-494930
Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506:328–33.
pubmed: 24522528 pmcid: 4991939 doi: 10.1038/nature13038
Thol F, Klesse S, Köhler L, Gabdoulline R, Kloos A, Liebich A, et al. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis. Leukemia. 2017;31:1286–95.
Camitta BM, Nathan DG, Forman EN, Parkman R, Rappeport JM, Orellana TD. Posthepatitic severe aplastic anemia–an indication for early bone marrow transplantation. Blood. 1974;43:473–83.
pubmed: 4150267 doi: 10.1182/blood.V43.4.473.473
Savola P, Martelius T, Kankainen M, Huuhtanen J, Lundgren S, Koski Y, et al. Somatic mutations and T-cell clonality in patients with immunodeficiency. Haematologica. 2020;105:2757–68
Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, et al. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun. 2018;9:1567.
Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kahsai O, et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood. 2009;114:4099–107.
pubmed: 19706884 pmcid: 2774550 doi: 10.1182/blood-2009-04-217604
Harden JL, Hamm D, Gulati N, Lowes MA, Krueger JG. Deep sequencing of the T-cell receptor repertoire demonstrates polyclonal T-cell infiltrates in psoriasis. F1000Res. 2015;4:460.
pubmed: 26594339 pmcid: 4648215 doi: 10.12688/f1000research.6756.1
Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000;28:27–30.
pubmed: 10592173 pmcid: 102409 doi: 10.1093/nar/28.1.27
Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2019;47:D941–7.
pubmed: 30371878 doi: 10.1093/nar/gky1015
Martincorena I, Campbell PJ. Somatic mutation in cancer and normal cells. Science. 2015;349:1483–9.
pubmed: 26404825 doi: 10.1126/science.aab4082
Martincorena I, Fowler JC, Wabik A, Lawson ARJ, Abascal F, Hall MWJ, et al. Somatic mutant clones colonize the human esophagus with age. Science. 2018;362:911–7.
pubmed: 30337457 pmcid: 6298579 doi: 10.1126/science.aau3879
Blokzijl F, de Ligt J, Jager M, Sasselli V, Roerink S, Sasaki N, et al. Tissue-specific mutation accumulation in human adult stem cells during life. Nature. 2016;538:260–4.
pubmed: 27698416 pmcid: 5536223 doi: 10.1038/nature19768
Yokoyama A, Kakiuchi N, Yoshizato T, Nannya Y, Suzuki H, Takeuchi Y, et al. Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature. 2019;565:312–7.
Nikolaev SI, Vetiska S, Bonilla X, Boudreau E, Jauhiainen S, Rezai Jahromi B, et al. Somatic activating KRAS mutations in arteriovenous malformations of the brain. N Engl J Med. 2018;378:250–61.
pubmed: 29298116 pmcid: 8161530 doi: 10.1056/NEJMoa1709449
Qi Q, Liu Y, Cheng Y, Glanville J, Zhang D, Lee J-Y, et al. Diversity and clonal selection in the human T-cell repertoire. Proc Natl Acad Sci USA. 2014;111:13139–44.
pubmed: 25157137 pmcid: 4246948 doi: 10.1073/pnas.1409155111
Callan MF, Steven N, Krausa P, Wilson JD, Moss PA, Gillespie GM, et al. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med. 1996;2:906–11.
Maini MK, Gudgeon N, Wedderburn LR, Rickinson AB, Beverley PC. Clonal expansions in acute EBV infection are detectable in the CD8 and not the CD4 subset and persist with a variable CD45 phenotype. J Immunol. 2000;165:5729–37.
pubmed: 11067931 doi: 10.4049/jimmunol.165.10.5729
Khan N, Shariff N, Cobbold M, Bruton R, Ainsworth JA, Sinclair AJ, et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol. 2002;169:1984–92.
pubmed: 12165524 doi: 10.4049/jimmunol.169.4.1984
Miles LA, Bowman RL, Merlinsky TR, Csete IS, Ooi AT, Durruthy-Durruthy R, et al. Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature. 2020;587:477–82.
Young AL, Challen GA, Birmann BM, Druley TE. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun. 2016;7:12484.
pubmed: 27546487 pmcid: 4996934 doi: 10.1038/ncomms12484
Arends CM, Galan-Sousa J, Hoyer K, Chan W, Jäger M, Yoshida K, et al. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia. 2018;32:1908–19.
pubmed: 29491455 doi: 10.1038/s41375-018-0047-7
Buscarlet M, Provost S, Zada YF, Bourgoin V, Mollica L, Dubé M-P, et al. Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A. Blood. 2018;132:277–80.
pubmed: 29764839 doi: 10.1182/blood-2018-01-829937
O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–28.
pubmed: 25587654 pmcid: 5634336 doi: 10.1146/annurev-med-051113-024537
Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009;27:591–619.
pubmed: 19132916 pmcid: 2740335 doi: 10.1146/annurev.immunol.021908.132706
Holmström TH, Schmitz I, Söderström TS, Poukkula M, Johnson VL, Chow SC, et al. MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly. EMBO J. 2000;19:5418–28.
Crescenzo R, Abate F, Lasorsa E, Tabbo F, Gaudiano M, Chiesa N, et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015;27:516–32.
pubmed: 25873174 pmcid: 5898430 doi: 10.1016/j.ccell.2015.03.006
Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JTV, Paradis V, et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med. 2011;208:1359–66.
pubmed: 21690253 pmcid: 3135371 doi: 10.1084/jem.20110283
Couronné L, Scourzic L, Pilati C, Valle Della V, Duffourd Y, Solary E, et al. STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica. 2013;98:1748–52.
pubmed: 23872306 pmcid: 3815176 doi: 10.3324/haematol.2013.085068
Ihantola E-L, Viisanen T, Gazali AM, Näntö-Salonen K, Juutilainen A, Moilanen L, et al. Effector T cell resistance to suppression and STAT3 signaling during the development of human type 1 diabetes. J Immunol. 2018;201:1144–53.
pubmed: 30006377 doi: 10.4049/jimmunol.1701199
Kerr CM, Clemente MJ, Chomczynski PW, Przychodzen B, Nagata Y, Adema V, et al. Subclonal STAT3 mutations solidify clonal dominance. Blood Adv. 2019;3:917–21.
pubmed: 30898763 pmcid: 6436009 doi: 10.1182/bloodadvances.2018027862
Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–98.
pubmed: 25426837 pmcid: 4306669 doi: 10.1056/NEJMoa1408617
Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111–21.
pubmed: 28636844 pmcid: 6717509 doi: 10.1056/NEJMoa1701719
Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355:842–7.
pubmed: 28104796 pmcid: 5542057 doi: 10.1126/science.aag1381
Frick M, Chan W, Arends CM, Hablesreiter R, Halik A, Heuser M, et al. Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2019;37:375–85
Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558:307–12.

Auteurs

Sofie Lundgren (S)

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. sofie.lundgren@helsinki.fi.
Translational Immunology Research program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland. sofie.lundgren@helsinki.fi.

Mikko A I Keränen (MAI)

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. mikko.a.keranen@helsinki.fi.
Translational Immunology Research program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland. mikko.a.keranen@helsinki.fi.
Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. mikko.a.keranen@helsinki.fi.

Matti Kankainen (M)

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Translational Immunology Research program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.
Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Jani Huuhtanen (J)

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Translational Immunology Research program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.
Department of Computer Science, School of Science, Aalto University, Espoo, Finland.

Gunilla Walldin (G)

Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.

Cassandra M Kerr (CM)

Translational Hematology and Oncology Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.

Michael Clemente (M)

Translational Hematology and Oncology Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.

Freja Ebeling (F)

Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.

Hanna Rajala (H)

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Translational Immunology Research program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.
Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.

Oscar Brück (O)

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Translational Immunology Research program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.

Harri Lähdesmäki (H)

Department of Computer Science, School of Science, Aalto University, Espoo, Finland.

Sari Hannula (S)

Institute of Molecular Medicine Finland, HILIFE, University of Helsinki, Helsinki, Finland.

Tiina Hannunen (T)

Institute of Molecular Medicine Finland, HILIFE, University of Helsinki, Helsinki, Finland.

Pekka Ellonen (P)

Institute of Molecular Medicine Finland, HILIFE, University of Helsinki, Helsinki, Finland.

Neal S Young (NS)

Hematology Branch, National Heart Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.

Seishi Ogawa (S)

Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Jaroslaw P Maciejewski (JP)

Translational Hematology and Oncology Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.

Eva Hellström-Lindberg (E)

Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.

Satu Mustjoki (S)

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. satu.mustjoki@helsinki.fi.
Translational Immunology Research program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland. satu.mustjoki@helsinki.fi.
ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland. satu.mustjoki@helsinki.fi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH